INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

THE NEED FOR REBLOZYL

Ineffective erythropoiesis in beta-thalassemia is characterized by2:

  • Increased proliferation of erythroid progenitors
  • Increased death of erythroid precursors
  • Impaired erythroid maturation
Drip bag icon

Ineffective erythropoiesis may lead to transfusion-dependent anemia2,3

There is a need to address ineffective erythropoiesis, improve anemia, and reduce transfusions in adult patients with beta-thalassemia

THE NEED FOR REBLOZYL

Ineffective erythropoiesis in beta-thalassemia is characterized by2:

  • Increased proliferation of erythroid progenitors
  • Increased death of erythroid precursors
  • Impaired erythroid maturation
Drip bag icon

Ineffective erythropoiesis may lead to transfusion-dependent anemia2,3

There is a need to address ineffective erythropoiesis, improve anemia, and reduce transfusions in adult patients with beta-thalassemia

References: 1. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219-1231. 2. Oikonomidou PR, Rivella S. What can we learn from ineffective erythropoiesis in thalassemia? Blood Rev. 2018;32(2):130-143. 3. Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014;123(25):3864-3872.